Suzanne Russo

Suzanne Russo

Auto-generated profile, based on publicly available information

Suzanne Russo

Department of Radiation Oncology, MetroHealth, Case Western Reserve University School of Medicine, Cleveland, OH

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Advances in Biological Regulation
Verified
Journal Article
Closed access
WCWilliam H. Chappell
William H. Chappell
SCSaverio Candido
Saverio Candido
SAStephen L. Abrams
Stephen L. Abrams
SRSuzanne Russo
Suzanne Russo
RORoger Ove
Roger Ove
JMJames A. McCubrey
James A. McCubrey

1 May 2013
Verified
Journal Article
Closed access
MSMuhammad Wasif Saif
Muhammad Wasif Saif
RORoger Ove
Roger Ove
JNJohn Ng
John Ng
SRSuzanne Russo
Suzanne Russo

1 September 2004 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
SYS. Ye
S. Ye
RORoger Ove
Roger Ove
SSS. Shen
S. Shen
SRS. Russo
S. Russo
IBI.A. Brezovich
I.A. Brezovich
Balloon catheter brachytherapy is becoming widely used in the treatment of early-stage breast cancer, due to its ease of use, short learning curve, and requirement of only one interstitial catheter through the breast. However, recent studies have shown that the dosimetry is not as simple as previously thought, due to iodine-containing radiographic contrast medium in the balloon, the lack of scatter medium, as well as source anisotropy.

10 May 2016 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
EFElisha Fredman
Elisha Fredman
DMDavid B. Mansur
David B. Mansur
SRSuzanne Russo
Suzanne Russo
Identifying the optimal treatment of pediatric Hodgkin’s disease has been at the forefront of clinical investigation in recent years. Results of a number of large clinical trials have driven paradigm shifts in how physicians approach this often curable disease. In an effort to balance the goals of maximizing survival while minimizing acute toxicities and late complications, the recommended indications, targets, doses and schedules of chemotherapy and radiation have and continue to evolve. Recent attempts to decrease the total volume of tissue receiving radiation without requiring a significant escalation in cytotoxic chemotherapy have shown promise in low, intermediate and high risk patients. Utilizing risk-adapted, response-based treatment, researchers hope to uncover a subpopulation that may not require previously considered standard treatment modalities.

22 July 2025 in Cancer Medicine
Verified
Journal Article
Open access
ECExpert Panel Management of Peritoneal Carcinomatosis
Expert Panel Management of Peritoneal Carcinomatosis
TKTimothy Kennedy
Timothy Kennedy
SSSareena Singh
Sareena Singh
GAGerard Abood
Gerard Abood
ECEric Christenson
Eric Christenson
SRSuzanne Russo
Suzanne Russo
Background: Multimodality therapy incorporating a combination of cytoreductive surgery (CRS), intraperitoneal (IP) and systemic therapy continues to evolve for peritoneal carcinomatosis (PC) However, treatment and outcomes vary depending on tumor of origin.Aims: To develop Appropriate Use Criteria (AUC) guidelines to facilitate treatment decision‐making for patients with PC based on available evidence.Materials and Methods: The American Radium Society (ARS) multidisciplinary expert panel performed a comprehensive systematic review. Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established modified Delphi consensus methodology.Results: Treatment of PC is often treated with a combination of CRS and IP ± systemic chemotherapy but specific recommendations exist for different tumor types and outcomes vary.Discussion: Treatment of PC is complex and varies depending on origin of primary tumor and extent of disease. These AUC assist in patient and treatment selection for different clinical scenarios.Conclusion: A summary of recommendations is outlined to guide practitioners on the management of PC from different tumor origins.

12 December 2013
Verified
Book Chapter
Closed access
PDF file
SRSuzanne Russo
Suzanne Russo
RORoger Ove
Roger Ove
LFLuis Fajardo
Luis Fajardo
JTJoel Tepper
Joel Tepper